Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 3,288 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $33.64, for a total transaction of $110,608.32. Following the completion of the transaction, the insider owned 48,719 shares of the company’s stock, valued at $1,638,907.16. This trade represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 0.7%

Castle Biosciences stock traded up $0.23 during midday trading on Wednesday, hitting $33.11. 243,174 shares of the stock were exchanged, compared to its average volume of 395,019. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The firm has a market cap of $1.01 billion, a P/E ratio of -50.17 and a beta of 0.94. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The company has a 50 day moving average price of $33.44 and a two-hundred day moving average price of $26.68.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. On average, sell-side analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CSTL. BTIG Research lifted their target price on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Roth Capital initiated coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target for the company. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, September 26th. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Finally, Robert W. Baird set a $36.00 price objective on Castle Biosciences in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Assetmark Inc. boosted its holdings in shares of Castle Biosciences by 9.3% in the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock valued at $142,000 after acquiring an additional 492 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Castle Biosciences during the second quarter worth approximately $26,000. Summit Global Investments raised its holdings in Castle Biosciences by 10.9% during the first quarter. Summit Global Investments now owns 13,718 shares of the company’s stock worth $337,000 after purchasing an additional 1,353 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Castle Biosciences by 188.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company’s stock worth $82,000 after purchasing an additional 1,371 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in Castle Biosciences by 0.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 160,663 shares of the company’s stock worth $3,944,000 after purchasing an additional 1,492 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.